Related Experiment Video
Updated: Feb 11, 2026

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials
David Andes1, Laura Kovanda2, A Desai2
1University of Wisconsin, Madison, Wisconsin, USA dra@medicine.wisc.edu.
Abstract:
Clinical use of voriconazole, posaconazole, and itraconazole revealed the need for therapeutic drug monitoring (TDM) of plasma concentrations of these antifungal agents. This need for TDM was not evident from clinical trials. In order to establish whether this requirement also applies to isavuconazole, we examined the plasma concentrations of 283 samples from patients receiving isavuconazole in clinical practice and compared the values with those from clinical trials. The concentration distributions from real-world use and clinical trials were nearly identical (>1 μg/ml in 90% of patients). These findings suggest that routine TDM may not be necessary for isavuconazole in most instances.
Insights
Routine therapeutic drug monitoring (TDM) may not be necessary for the antifungal isavuconazole. Real-world patient plasma concentrations closely matched clinical trial data, suggesting TDM is not typically required.
Area of Science:
- Medical Mycology
- Pharmacokinetics
- Clinical Pharmacy
Background:
- Voriconazole, posaconazole, and itraconazole require therapeutic drug monitoring (TDM) due to variable plasma concentrations.
- This necessity for TDM was not apparent during their respective clinical trials.
- The need for TDM in isavuconazole, another important antifungal, remained undetermined.
Purpose of the Study:
- To determine if routine therapeutic drug monitoring (TDM) is necessary for isavuconazole.
- To compare isavuconazole plasma concentrations in clinical practice with those from clinical trials.
Main Methods:
- Analysis of 283 patient plasma samples from real-world isavuconazole use.
- Comparison of observed concentration distributions with data from isavuconazole clinical trials.
Main Results:
- Plasma concentration distributions for isavuconazole in clinical practice were nearly identical to those in clinical trials.
- Over 90% of patients in both settings achieved concentrations above 1 μg/ml.
Conclusions:
- Routine therapeutic drug monitoring (TDM) is likely not necessary for isavuconazole in most clinical situations.
- Isavuconazole exhibits predictable pharmacokinetics, unlike some other azole antifungals.
- Clinical trial data adequately predict real-world isavuconazole exposure.
More Related Videos
05:16Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
Published on: May 7, 2020
14:45Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay
Published on: September 16, 2012
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Statistical Software for Data Analysis and Clinical Trials
Trial and Error and Algorithm
Concentration Cells
Consider the following voltaic cell:
Solution Concentration and Dilution